ASPENBeiGeneEHAESMONSCLCPD-1Waldenström

Pivotal phase 3 study of Zanubrutinib vs Ibrutinib in R/R CLL/SLL

 Volver  Ver
Pivotal phase 3 study of Zanubrutinib vs Ibrutinib in R/R CLL/SLL
 IMAGE   06/2020
 Ver

Pivotal phase 3 study of Zanubrutinib vs Ibrutinib in R/R CLL/SLL

Rating

Rate this publication

Publicaciones relacionadas

Zanubrutinib vs. Bendamustine in previously untreated CLL/SLL
Zanubrutinib vs. Bendamustine in previously untreated CLL/SLL
Zanubrutinib vs. Ibrutinib in R/R CLL/SLL
Zanubrutinib vs. Ibrutinib in R/R CLL/SLL
Trial in progress: a phase 2, multicenter, single-arm study of zanubrutinib (BGB-3111) in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma intolerant of prior treatment with ibrutinib
Trial in progress: a phase 2, multicenter, single-arm study of zanubrutinib (BGB-3111) in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma intolerant of prior treatment with ibrutinib
 Volver